OverviewSuggest Edit

Verona Pharma plc is a United Kingdom-based bio-pharmaceutical company. The Company is engaged in developing drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Its program is RPL554, an inhaled, dual phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) inhibitors, as a nebulized treatment for patients in hospital with acute exacerbation of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. RPL554 has completed two double-blind placebo controlled randomized Phase II b studies of RPL554: one in mild to moderate asthma and another in mild to moderate COPD. Its other products include VRP700 and NAIPs. VRP700 is an anti-tussive (cough) drug and has completed a Phase II trial. The Company's subsidiaries include Rhinopharma Limited and Verona Pharma Inc.
TypePublic
HQLondon, GB
Websiteveronapharma.com

Latest Updates

Employees (est.) (Nov 2020)33
Share Price (Oct 2020)£0.6(+6%)
Cybersecurity ratingCMore

Key People/Management at Verona Pharma

David Ebsworth

David Ebsworth

Non-Executive Chairperson of the Board
Ken Cunningham

Ken Cunningham

Non-Executive Director
Martin Edwards

Martin Edwards

Non-Executive Director
David Zaccardelli

David Zaccardelli

Director, President and Chief Executive Officer
Kathleen Rickard

Kathleen Rickard

Chief Medical Officer
Mahendra G. Shah

Mahendra G. Shah

Non-Executive Director
Show more

Verona Pharma Office Locations

Verona Pharma has offices in London, Cardiff and Raleigh
London, GB (HQ)
3 More London Riverside
Cardiff, GB
One Central Square
Raleigh, NC, US
8045 Arco Corporate Dr
Show all (3)

Verona Pharma Financials and Metrics

Verona Pharma Revenue

GBP

Net income (FY, 2018)

(19.9m)

EBITDA (FY, 2018)

(25.6m)

EBIT (FY, 2018)

(25.6m)

Market capitalization (29-Oct-2020)

228.0m

Closing stock price (29-Oct-2020)

0.6

Cash (31-Dec-2018)

19.8m
Verona Pharma's current market capitalization is £228 m.
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

EBITDA

(1.3m)(1.5m)(1.6m)(1.9m)(1.8m)(2.6m)(2.8m)(3.7m)(8.9m)(6.9m)(29.7m)(25.6m)

EBIT

11.4k671.1k(1.3m)(1.5m)(1.6m)(1.9m)(1.8m)(2.6m)(2.8m)(3.8m)(9.0m)(7.0m)(29.8m)(25.6m)

Pre tax profit

26.0k(608.4k)(1.2m)(1.3m)(1.6m)(1.9m)(1.8m)(2.6m)(2.8m)(3.8m)(9.0m)(6.0m)(25.2m)(24.1m)

Income tax expense

(27.9k)(4.5k)124.4k48.1k289.4k1.0m1.5m954.0k4.7m4.2m
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

982.4k1.1m1.3m2.5m2.8m2.0m2.5m960.9k603.8k10.0m3.5m39.8m31.4m19.8m

Current Assets

991.3k2.4m1.5m2.5m3.2m2.1m2.6m1.2m853.4k11.3m5.6m43.8m87.1m71.7m

PP&E

17.4k16.1k14.1k18.0k15.5k6.0k39.5k27.6k21.8k13.2k14.0k16.0k21.0k

Goodwill

1.8m2.3m2.3m
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

26.0k(608.4k)(1.2m)(1.4m)(1.6m)(1.9m)(1.7m)(2.5m)(2.5m)(2.8m)(7.5m)(5.0m)(20.5m)(19.9m)

Cash From Operating Activities

351.3k1.2m(1.3m)(1.6m)(1.7m)(1.7m)(2.6m)(2.3m)(3.5m)(6.4m)(5.6m)(20.7m)(18.1m)

Cash From Financing Activities

1.7m2.4m2.0m873.9k2.1m1.0m1.8m13.1m41.2m63.2m

Net Change in Cash

80.8k188.8k1.2m375.1k(827.0k)523.2k(1.6m)(357.1k)9.4m(6.4m)35.6m(6.9m)(12.8m)
GBPFY, 2005

Financial Leverage

1 x
Show all financial metrics

Verona Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Verona Pharma Online and Social Media Presence

Embed Graph

Verona Pharma News and Updates

Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference

Posters highlight ensifentrine’s safety profile and its potential to improve lung function and quality of life irrespective of COPD severity Posters highlight ensifentrine’s safety profile and its potential to improve lung function and quality of life irrespective of COPD severity

Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

ENHANCE Phase 3 program enrollment continues on track to complete in 2H21

Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease

Ensifentrine improves lung function and quality of life when added to maintenance tiotropium Ensifentrine improves lung function and quality of life when added to maintenance tiotropium

Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces data from a pilot study of a pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine …

Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three months ended March 31, 2021 on Thursday, Ap…

Lisa Deschamps Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces, effective March 1, 2021, Ms. Lisa Deschamps has joined the board as a Non-Executive Director.
Show more

Verona Pharma Frequently Asked Questions

  • Who are Verona Pharma key executives?

    Verona Pharma's key executives are David Ebsworth, Ken Cunningham and Martin Edwards.

  • How many employees does Verona Pharma have?

    Verona Pharma has 33 employees.

  • Who are Verona Pharma competitors?

    Competitors of Verona Pharma include ReCode Therapeutics, Servier and Patheon.

  • Where is Verona Pharma headquarters?

    Verona Pharma headquarters is located at 3 More London Riverside, London.

  • Where are Verona Pharma offices?

    Verona Pharma has offices in London, Cardiff and Raleigh.

  • How many offices does Verona Pharma have?

    Verona Pharma has 3 offices.